• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

ARVO 2024: Repeatability of FLIO and erythrocyte velocities in a nonhuman primate glaucoma model


Osamah Saeedi, MD, MS, details his ARVO 2024 presentation and the study finding's implications on monitoring and treating glaucoma.

Osamah Saeedi, MD, MS, gives an overview of study results in his ARVO 2024 presentation, "Repeatability of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) and Erythrocyte Velocities in a Nonhuman Primate Glaucoma Model," which found is that erythrocyte mediated angiography were highly repeatable.

Video Transcript

Editor’s note - The following transcript has been lightly edited for clarity.

Osamah Saeedi MD, MS:

I'm at ARVO 2024. Yesterday, I presented at the ARVO OVI conference, I presented a poster entitled, "The Repeatability and Reproducibility of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) and Erythrocyte Mediated Angiography in a Non-human Primate Model." The key findings here are we adjusted intraocular pressure in a non-human, in an acute IOP elevation model, in a nonhuman primate. And what we found essentially that the fluorescence lifetime imaging ophthalmoscopy and erythrocyte mediated angiography were highly, erythrocyte mediated angiography were highly repeatable in this model. This is particularly important, because both of these modalities are going to give us further insight, potentially, into the metabolic and non-pressure related changes in glaucoma. So we wanted to make sure that they were not affected by intraocular pressure. While this work is early, it is important as glaucoma specialists that we look for biomarkers for the disease that are not related to intraocular pressure. Hence, knowing the metabolic activity of a tissue, knowing the retinal blood flow, may ultimately help us both monitor the disease early on in, the in the process, as well as develop new treatments that are not related to intraocular pressure. So we have now established that these measurements are highly repeatable in this model of glaucoma, and so we will now look at the long-term changes with elevated intraocular pressure chronically in this model.

Related Videos
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Shelley Cutler, OD, FAAO, outlines her key takeaways from this year's IKA symposium
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.